The future of adjuvant therapy for renal cell carcinoma

Clinical Practice

Volumn 9, Issue 4, 2012, Pages 451-462

  Welsh, Sarah J ^a   Janowitz, Tobias ^a   Eisen, Tim ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ALPHA INTERFERON; AXITINIB; BCG VACCINE; BEVACIZUMAB; CELECOXIB; DOCETAXEL; EVEROLIMUS; GIRENTUXIMAB; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 2; MEDROXYPROGESTERONE ACETATE; PAZOPANIB; PLACEBO; PREDNISOLONE; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA2B INTERFERON; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR CELL VACCINE; VASCULOTROPIN; VITESPEN; ZOLEDRONIC ACID;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; GENE MUTATION; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; NEPHRECTOMY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; UNSPECIFIED SIDE EFFECT;

EID: 84865514212     PISSN: 20449038     EISSN: 20449046     Source Type: Journal    
DOI: 10.2217/cpr.12.39     Document Type: Review

References (56)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. Cancer J. Clin. 59, 225-249 (2009).
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18(3), 581-592 (2007).
3. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 281, 1628-1631 (1999).
4. Hollingsworth JM, Miller DC, Dunn RL et al. Surgical management of low-stage renal cell carcinoma: Technology does not supersede biology. Urology 67, 1175-1180 (2006).
5. Leibovich BC, Blute ML, Cheville JC et al. Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy. J. Urol. 171, 1066-1070 (2004).
6. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: Analysis of the National Cancer Data Base. Cancer 113, 78-83 (2008).
7. DeVita VT Jr, Hellman S, Rosenberg SA. Cancer Principles and Practice of Oncology (8th Edition). Lippincott Williams and Wilkins, Philadelphia, PA, USA (2008).
8. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J. Clin. Oncol. 19, 1649-1657 (2001).
9. Zisman A, Pantuck AJ, Wieder J et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 20, 4559-4566 (2002). nFirst to describe the UCLA integrated scoring system to predict risk of relapse after surgery in renal cell carcinoma (RCC) patients.
10. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: The SSIGN score. J. Urol. 168, 2395-2400 (2002). nDemonstrated that tumor stage, tumor size, nuclear grade and histologic tumor necrosis could predict progression to metastatic RCC in patients with clear cell RCC.
11. Leibovich BC, Blute ML, Cheville JC et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: A stratification tool for prospective clinical trials. Cancer 97, 1663-1671 (2003). nForms the basis for development of the Leibovich score used in some of the ongoing adjuvant trials.
12. Ficarra V, Novara G, Galfano A et al. The 'stage, size, grade and necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int. 103, 165-170 (2009).
13. Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up. J. Clin. Oncol. 11, 1368-1375 (1993).
14. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6(Suppl. 1), S55-S57 (2000).
15. Messing EM, Manola J, Wilding G et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trial. J. Clin. Oncol. 21, 1214-1222 (2003).
16. Pizzocaro G, Piva L, Colavita M et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study. J. Clin. Oncol. 19, 425-431 (2001).
17. Clark JI, Atkins MB, Urba WJ et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A Cytokine Working Group randomized trial. J. Clin. Oncol. 21, 3133-3140 (2003).
18. Majhail NS, Wood L, Elson P, Finke J, Olencki T, Bukowski RM. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: A pilot study. Clin. Genitourin. Cancer 5, 50-56 (2006).
19. Galligioni E, Quaia M, Merlo A et al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guèrin: Five-year results of a prospective randomized study. Cancer 77, 2560-2566 (1996).
20. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 363, 594-599 (2004).
21. Wood C, Srivastava P, Bukowski R et al.; C-100-112 RCC Study Group. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised Phase III trial. Lancet 372, 145-154 (2008).
22. Pizzocaro G, Piva L, Di Fronzo G et al. Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J. Urol. 138, 1379-1381 (1987).
23. Atzpodien J, Schmitt E, Gertenbach U et al. Adjuvant treatment with interleukin-2- And interferon-Alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: Results of a prospectively randomised trial of the German Cooperative Renal Carcinoma hemoimmunotherapy Group (DGCIN). Br. J. Cancer 92, 843-846 (2005).
24. Drucker BJ. Renal cell carcinoma: Durrent status and future prospects. Cancer Treat. Rev. 31, 536-545 (2005).
25. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260, 1317-1320 (1993).
26. Young AC, Craven RA, Cohen D et al. Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin. Cancer Res. 15(24), 7582 (2009).
27. Maxwell PH, Wiesener MS, Chang GW et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733), 271-275 (1999). n nExplains how levels of hypoxia inducible factor (HIF)-A subunits are regulated by VHL and is a seminal paper in HIF biology.
28. Maxwell PH, Dachs GU, Gleadle JM et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl Acad. Sci. USA 94, 8104-8109 (1997).
29. Wiesner M, Munchenhagen P, Berger I et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1a in clear cell renal carcinomas. Cancer Res. 61, 5215-5222 (2001).
30. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate K. Up-regulation of hypoxia-inducible factors HIF-1a and HIF-2a under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19, 5435-5443 (2000).
31. Turner KJ, Moore JW, Jones A et al. Expression of hypoxia-inducible factors in human renal cancer: Relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res. 62, 2957-2961 (2002).
32. Semenza GL. Oxygen homeostasis. Wiley Interdiscip. Rev. Syst. Biol. Med. 2(3), 336-361 (2010).
33. Kim WY, Kaelin WG Jr. Molecular pathways in renal cell carcinoma - rationale for targeted treatment. Semin. Oncol. 33(5), 588-595 (2006).
34. Singer EA, Gupta GN, Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr. Opin Oncol. 24(3), 284-290 (2012). nUseful review of current and future targeted therapies in RCC.
35. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: Exploiting the hypoxia-induced pathway. Clin. Cancer Res. 9, 4641-4652 (2003).
36. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
37. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon-A in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
38. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon-A-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind Phase III trial. Lancet 370, 2103-2111 (2007).
39. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized Phase III trial. J. Clin. Oncol. 28, 1061-1068 (2010).
40. Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1a expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res. 60, 1541-1545 (2000).
41. Zundel W, Schindler C, Haas-Kogan D et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14, 391-396 (2000).
42. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2(neu) signaling increases the rate of hypoxia-inducible factor 1a (HIF-1a) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol. 21, 3995-4004 (2001).
43. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon-A, or both for advanced renal cell carcinoma. N. Engl. J. Med. 356, 2271-2281 (2007).
44. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors. Cancer 116, 4256-4265 (2010).
45. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled Phase III trial. Lancet 372, 449-456 (2008).
46. Shuch B, Li Z, Belldegrun AS. Carbonic anhydrase IX and renal cell carcinoma: Prognosis, response to systemic therapy, and future vaccine strategies. BJU Int. 101, 25-30 (2008).
47. Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3), 220-231 (2009).
48. Bhargava P, Robinson MO. Development of second-generation VEGFR tyrosine kinase inhibitors: Durrent status. Curr. Oncol. Rep. 13(2), 103-111 (2011).
49. Ravaud A, Bello CL. Exposure-response relationships in patients with metastatic renal cell carcinoma receiving sunitinib: Maintaining optimum efficacy in clinical practice. Anticancer Drugs 22(5), 377-383 (2011).
50. McGuire BB, Fitzpatrick JM. Biomarkers in renal cell carcinoma. Curr. Opin Urol. 19, 441-446 (2009).
51. Zurita AJ, Jonasch E, Wu HK, Tran HT, Heymach JV. Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 115, 2346-2354 (2009).
52. Yuasa T, Takahashi S, Hataki K, Yonese J, Fukui I. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cancer. Cancer Sci. 102, 1949-1957 (2011).
53. Parmar MK. Speeding up the evaluation of new agents in cancer. J. Natl Cancer Inst. 100(17), 1204-1214 (2008). nGood review and explanation of the multiarm multistage (MAMS) trial design.
54. James ND, Sydes MR, Clarke NW et al. STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer - A multi-Arm multi-stage randomised controlled trial. Clin. Oncol. 20(8), 577-581 (2008).
55. James ND, Sydes MR, Clarke NW et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): A multi-Arm, multistage randomized controlled trial. BJU Int. 103(4), 464-469 (2009).
56. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995-2005 (2011).